Strategies to discover unexpected targets for drugs active at G protein-coupled receptors

Annual Review of Pharmacology and Toxicology

Volumn 51, Issue , 2011, Pages 117-144

  Allen, John A ^a   Roth, Bryan L ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

drug side effects; high throughput screening; polypharmacology; receptorome; similarity ensemble approach; valvulopathy

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ARRESTIN; CLOZAPINE; DELAVIRDINE; DOMPERIDONE; FENFLURAMINE; FLUOXETINE; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR AGONIST; G PROTEIN COUPLED RECEPTOR ANTAGONIST; GUANFACINE; IFENPRODIL TARTRATE; KAPPA OPIATE RECEPTOR; KETANSERIN; LISURIDE; LITHIUM; LORCASERIN; METHADONE; MUSCARINIC AGENT; NETAMIFTIDE; NEUROLEPTIC AGENT; PERGOLIDE; PHENTERMINE; QUINIDINE; ROFECOXIB; SALBUTAMOL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AGRANULOCYTOSIS; AMINO TERMINAL SEQUENCE; ANALYTIC METHOD; ARTICLE; ASTHMA; BIOINFORMATICS; CARBOXY TERMINAL SEQUENCE; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CHEMINFORMATICS; DIABETES MELLITUS; DRUG DESIGN; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; HEART ARRHYTHMIA; HIGH THROUGHPUT SCREENING; HUMAN; LIGAND BINDING; MOLECULAR MODEL; NONHUMAN; PARKINSON DISEASE; POLYPHARMACY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SALVIA; SCHIZOPHRENIA; SEIZURE; SIDE EFFECT; SIGNAL TRANSDUCTION; TACHYCARDIA; VALVULAR HEART DISEASE; WEIGHT GAIN;

ANIMALS; COMPUTATIONAL BIOLOGY; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG DISCOVERY; HUMANS; LIGANDS; PHARMACEUTICAL PREPARATIONS; RECEPTORS, G-PROTEIN-COUPLED;

EID: 79951512210     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-010510-100553     Document Type: Article

References (140)

1. King N, Hittinger CT, Carroll SB. 2003. Evolution of key cell signaling and adhesion protein families predates animal origins. Science 301:361-63 (Pubitemid 36877069)
2. Schioth HB, Nordstrom KJ, Fredriksson R. 2007. Mining the gene repertoire and ESTs for G protein-coupled receptors with evolutionary perspective. Acta Physiol. 190:21-31 (Pubitemid 46570177)
3. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, et al. 2001. The sequence of the human genome. Science 291:1304-51 (Pubitemid 32173090)
4. Kristiansen K. 2004. Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis approaches to receptor structure and function. Pharmacol. Ther. 103:21-80 (Pubitemid 38891912)
5. Kroeze WK, Sheffler DJ, Roth BL. 2003. G-protein-coupled receptors at a glance. J. Cell Sci. 116:4867-69 (Pubitemid 38016693)
6. Thompson MD, Burnham WM, Cole DE. 2005. The G protein-coupled receptors: pharmacogenetics and disease. Crit. Rev. Clin. Lab. Sci. 42:311-92 (Pubitemid 41647725)
7. Lagerstrom MC, Schioth HB. 2008. Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat. Rev. Drug Discov. 7:339-57
8. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, et al. 2000. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289:739-45 (Pubitemid 30650186)
9. 2- adrenergic G protein-coupled receptor. Science 318:1258-65 (Pubitemid 350172884)
10. 2A adenosine receptor bound to an antagonist. Science 322:1211-17
11. Armbruster BN, Roth BL. 2005. Mining the receptorome. J. Biol. Chem. 280:5129-32 (Pubitemid 40279980)
12. DeWire SM, Ahn S, Lefkowitz RJ, Shenoy SK. 2007. β-arrestins and cell signaling. Annu. Rev. Physiol. 69:483-510
13. Gilman AG. 1995. G proteins and regulation of adenylyl cyclase. Biosci. Rep. 15:65-97
14. Rodbell M. 1995. Signal transduction: evolution of an idea. Environ. Health Perspect. 103:338-45
15. Milligan G, Kostenis E. 2006. Heterotrimeric G-proteins: a short history. Br. J. Pharmacol. 147(Suppl. 1):S46-55 (Pubitemid 43077261)
16. Shenoy SK, Drake MT, Nelson CD, Houtz DA, Xiao K, et al. 2006. β-arrestin-dependent, G protein-independent ERK1/2 activation by the β2 adrenergic receptor. J. Biol. Chem. 281:1261-73
17. Ferguson SS, Downey WE III, Colapietro AM, Barak LS, Menard L, Caron MG. 1996. Role of β-arrestin in mediating agonist-promoted G protein-coupled receptor internalization. Science 271:363-66
18. Ferguson SSG. 2001. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol. Rev. 53:1-24 (Pubitemid 32173106)
19. Shenoy SK, Lefkowitz RJ. 2005. Seven-transmembrane receptor signaling through β-arrestin. Sci. STKE 2005(308):cm10
20. Fredriksson R, Lagerstrom MC, Lundin LG, Schioth HB. 2003. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol. Pharmacol. 63:1256-72 (Pubitemid 36627220)
21. Chung S, Funakoshi T, Civelli O. 2008. Orphan GPCR research. Br. J. Pharmacol. 153(Suppl. 1):S339-46 (Pubitemid 351341000)
22. Harrold JA, Halford JC. 2007. Orphan G-protein-coupled receptors: strategies for identifying ligands and potential for use in eating disorders. Drugs R&D 8:287-99 (Pubitemid 47403124)
23. Vassilatis DK, Hohmann JG, Zeng H, Li F, Ranchalis JE, et al. 2003. The G protein-coupled receptor repertoires of human and mouse. Proc. Natl. Acad. Sci. USA 100:4903-8 (Pubitemid 36457826)
24. Cullum VA, Farmer JB, Jack D, Levy GP. 1969. Salbutamol: a new, selective β-adrenoceptive receptor stimulant. Br. J. Pharmacol. 35:141-51
25. 2A receptor desensitization and resensitization reveal an arrestin-, GRK2-, and GRK5-independent mode of regulation in human embryonic kidney 293 cells. Mol. Pharmacol. 60:1020-30 (Pubitemid 33027437)
26. 2A serotonin receptor functional selectivity. Mol. Pharmacol. 77:327-38
27. Keiser MJ, Roth BL, Armbruster BN, Ernsberger P, Irwin JJ, Shoichet BK. 2007. Relating protein pharmacology by ligand chemistry. Nat. Biotechnol. 25:197-206 (Pubitemid 46227119)
28. Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, et al. 2009. Predicting new molecular targets for known drugs. Nature 462:175-81
29. Conn PJ, Jones CK, Lindsley CW. 2009. Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Trends Pharmacol. Sci. 30:148-55
30. 1 agonism a prerequisite for mimicking clozapine's actions? Psychopharmacology 178:451-60 (Pubitemid 40486985)
31. 1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. J. Neurosci. 28:10422-33
32. 4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties. Neuropsychopharmacology 35:855-69
33. Raschi E, Ceccarini L, De Ponti F, Recanatini M. 2009. hERG-related drug toxicity and models for predicting hERG liability and QT prolongation. Expert Opin. Drug Metab. Toxicol. 5:1005-21
34. Hopkins AL. 2008. Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol. 4:682-90
35. Roth BL, Sheffler DJ, Kroeze WK. 2004. Magic shotguns versus magic bullets: selectively nonselective drugs for mood disorders and schizophrenia. Nat. Rev. Drug Discov. 3:353-59 (Pubitemid 38499762)
36. Pert CB, Pasternak G, Snyder SH. 1973. Opiate agonists and antagonists discriminated by receptor binding in brain. Science 182:1359-61
37. Pert CB, Snyder SH. 1973. Opiate receptor: demonstration in nervous tissue. Science 179:1011-14
38. Alouani S. 2000. Scintillation proximity binding assay. Methods Mol. Biol. 138:135-41
39. Banks P, Harvey M. 2002. Considerations for using fluorescence polarization in the screening of G protein-coupled receptors. J. Biomol. Screen. 7:111-17 (Pubitemid 34493709)
40. Christopoulos A, Kenakin T. 2002. G protein-coupled receptor allosterism and complexing. Pharmacol. Rev. 54:323-74 (Pubitemid 34575719)
41. i-coupled receptors. Anal. Biochem. 270:242-48 (Pubitemid 29252535)
42. EmkeyR, Rankl NB. 2009. ScreeningG protein-coupled receptors: measurement ofintracellular calcium using the fluorometric imaging plate reader. Methods Mol. Biol. 565:145-58
43. Wise A, Jupe SC, Rees S. 2004. The identification of ligands at orphan G-protein coupled receptors. Annu. Rev. Pharmacol. Toxicol. 44:43-66 (Pubitemid 38263833)
44. 16 the optimal tool for fishing ligands of orphan G-protein-coupled receptors? Trends Pharmacol. Sci. 22:560-64 (Pubitemid 33042645)
45. Kenakin T. 2008. Functional selectivity in GPCR modulator screening. Comb. Chem. High Throughput Screen. 11:337-43 (Pubitemid 351830304)
46. Kenakin T. 2008. Functional assays as prismatic views of drug activity: relevance to new drug discovery. J. Recept. Signal Transduct. 28:109-25 (Pubitemid 351588079)
47. Hermans E. 2003. Biochemical and pharmacological control of the multiplicity of coupling at G-protein-coupled receptors. Pharmacol. Ther. 99:25-44 (Pubitemid 36694748)
48. Wong SKF. 2003. G protein selectivity is regulated by multiple intracellular regions of GPCRs. Neurosignals 12:1-12
49. DiPilato LM, Cheng X, Zhang J. 2004. Fluorescent indicators of cAMP and Epac activation reveal differential dynamics of cAMP signaling within discrete subcellular compartments. Proc. Natl. Acad. Sci. USA 101:16513-18 (Pubitemid 39557744)
50. Fan F, Binkowski BF, Butler BL, Stecha PF, Lewis MK, Wood KV. 2008. Novel genetically encoded biosensors using firefly luciferase. Am. Chem. Soc. Chem. Biol. 3:346-51
51. Kimple AJ, Soundararajan M, Hutsell SQ, Roos AK, Urban DJ, et al. 2009. Structural determinants of G-protein αsubunit selectivity by regulator of G-protein signaling 2 (RGS2). J. Biol. Chem. 284:19402-11
52. Barak LS, Ferguson SSG, Zhang J, Caron MG. 1997. A β-arrestin/green fluorescent protein biosensor for detecting G protein-coupled receptor activation. J. Biol. Chem. 272:27497-500 (Pubitemid 27473532)
53. Masri B, Salahpour A, Didriksen M, Ghisi V, Beaulieu JM, et al. 2008. Antagonism of dopamine D2 receptor/β-arrestin 2 interaction is a common property of clinically effective antipsychotics. Proc. Natl. Acad. Sci. USA 105:13656-61
54. Hamdan FF, Audet M, Garneau P, Pelletier J, Bouvier M. 2005. High-throughput screening of G protein-coupled receptor antagonists using a bioluminescence resonance energy transfer 1-based β-arrestin2 recruitment assay. J. Biomol. Screen. 10:463-75 (Pubitemid 41233225)
55. Barnea G, Strapps W, Herrada G, Berman Y, Ong J, et al. 2008. The genetic design of signaling cascades to record receptor activation. Proc. Natl. Acad. Sci. USA 105:64-69
56. 2B receptor agonists: implications for drug safety assessment. Mol. Pharmacol. 76:710-22
57. Morfis M, Christopoulos A, Sexton PM. 2003. RAMPs: 5 years on, where to now? Trends Pharmacol. Sci. 24:596-601 (Pubitemid 37357144)
58. Chalmers DT, Behan DP. 2002. The use of constitutively active GPCRs in drug discovery and functional genomics. Nat. Rev. Drug Discov. 1:599-608 (Pubitemid 37361523)
59. s αsubunit. Science 250:121-23 (Pubitemid 20374972)
60. Pausch MH. 1997. G-protein-coupled receptors in Saccharomyces cerevisiae: high-throughput screening assays for drug discovery. Trends Biotechnol. 15:487-94 (Pubitemid 27504846)
61. Briscoe CP, Tadayyon M, Andrews JL, Benson WG, Chambers JK, et al. 2003. The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. J. Biol. Chem. 278:11303-11 (Pubitemid 36792687)
62. Dowell SJ, Brown AJ. 2002. Yeast assays for G-protein-coupled receptors. Recept. Channels 8:343-52 (Pubitemid 35460477)
63. 3 mus-carinic acetylcholine receptors using a Saccharomyces cerevisiae platform. Am. Chem. Soc. Chem. Biol. 5(4):365-75
64. Armbruster BN, Li X, Pausch MH, Herlitze S, Roth BL. 2007. Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand. Proc. Natl. Acad. Sci. USA 104:5163-68 (Pubitemid 47186193)
65. Dong S, Rogan SC, Roth BL. 2010. Directed molecular evolution of DREADDs: a generic approach to creating next-generation RASSLs. Nat. Protoc. 5:561-73
66. Menzaghi F, Behan DP, Chalmers DT. 2002. Constitutively activated G protein-coupled receptors: a novel approach to CNS drug discovery. Curr. Drug Targets CNS Neurol. Disord. 1:105-21
67. Heilker R, Wolff M, Tautermann CS, Bieler M. 2009. G-protein-coupled receptor-focused drug discovery using a target class platform approach. Drug Discov. Today 14:231-40
68. Strachan RT, Allen JA, Sheffler DJ, Roth BL. p90 ribosomal S6 kinase 2, a novel GPCR kinase, is required for growth factor-mediated attenuation of GPCR signaling. Biochemistry 49:2657-71
69. 2A serotonin receptors by scaffolding proteins and kinases. Neuropharmacology 55:961-68
70. Haasen D, Schnapp A, Valler MJ, Heilker R. 2006. G protein-coupled receptor internalization assays in the high-content screening format. Methods Enzymol. 414:121-39 (Pubitemid 44716220)
71. Osmond RIW, Sheehan A, Borowicz R, Barnett E, Harvey G, et al. 2005. GPCR screening via ERK 1/2: a novel platform for screening G protein-coupled receptors. J. Biomol. Screen. 10:730-37 (Pubitemid 41476808)
72. Siehler S. 2008. Cell-based assays in GPCR drug discovery. Biotechnol. J. 3:471-83 (Pubitemid 351618733)
73. Granas C, Lundholt BK, Heydorn A, Linde V, Pedersen HC, et al. 2005. High content screening for G protein-coupled receptors using cell-based protein translocation assays. Comb. Chem. High Throughput Screen. 8:301-9 (Pubitemid 40694866)
74. Saini DK, Gautam N. 2010. Live cell imaging for studying G protein-coupled receptor activation in single cells. Methods Mol. Biol. 617:191-207
75. Borchert KM, Galvin RJ, Frolik CA, Hale LV, Halladay DL, et al. 2005. High-content screening assay for activators of the Wnt/Fzd pathway in primary human cells. Assay Drug Dev. Technol. 3:133-41 (Pubitemid 40846883)
76. Oakley RH, Hudson CC, Sjaastad MD, Loomis CR. 2006. The ligand-independent translocation assay: an enabling technology for screening orphan G protein-coupled receptors by arrestin recruitment. Methods Enzymol. 414:50-63 (Pubitemid 44716216)
77. Ozawa A, Lindberg I, Roth B, Kroeze WK. 2010. Deorphanization of novel peptides and their receptors. Am. Assoc. Pharm. Sci. J. 12:378-84
78. Xiao SH, Reagan JD, Lee PH, Fu A, Schwandner R, et al. 2008. High throughput screening for orphan and liganded GPCRs. Comb. Chem. High Throughput Screen. 11:195-215 (Pubitemid 351480893)
79. Regard JB, Sato IT, Coughlin SR. 2008. Anatomical profiling of G protein-coupled receptor expression. Cell 135:561-71
80. Mestres J, Gregori-Puigjane E. 2009. Conciliating binding efficiency and polypharmacology. Trends Pharmacol. Sci. 30:470-74
81. Mestres J, Gregori-Puigjane E, Valverde S, Sole RV. 2009. The topology of drug-target interaction networks: implicit dependence on drug properties and target families. Mol. Biosyst. 5:1051-57
82. Hert J, Keiser MJ, Irwin JJ, Oprea TI, Shoichet BK. 2008. Quantifying the relationships among drug classes. J. Chem. Inf. Model. 48:755-65 (Pubitemid 351757743)
83. DeGraw AJ, Keiser MJ, Ochocki JD, Shoichet BK, Distefano MD. 2010. Prediction and evaluation of protein farnesyltransferase inhibition by commercial drugs. J. Med. Chem. 53:2464-71
84. Hopkins AL, Groom CR. 2002. The druggable genome. Nat. Rev. Drug Discov. 1:727-30 (Pubitemid 37361545)
85. Gaulton A, Attwood TK. 2003. Bioinformatics approaches for the classification of G-protein-coupled receptors. Curr. Opin. Pharmacol. 3:114-20 (Pubitemid 36411233)
86. Sreekumar KR, Huang Y, Pausch MH, Gulukota K. 2004. Predicting GPCR-G-protein coupling using hidden Markov models. Bioinformatics 20:3490-99 (Pubitemid 40136784)
87. Small KM, McGraw DW, Liggett SB. 2003. Pharmacology and physiology of human adrenergic receptor polymorphisms. Annu. Rev. Pharmacol. Toxicol. 43:381-411 (Pubitemid 37372647)
88. Ballesteros JA, Shi L, Javitch JA. 2001. Structural mimicry in G protein-coupled receptors: implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors. Mol. Pharmacol. 60:1-19 (Pubitemid 32595228)
89. Shapiro DA, Kristiansen K, Weiner DM, Kroeze WK, Roth BL. 2002. Evidence for a model of agonist-induced activation of 5-hydroxytryptamine 2A serotonin receptors that involves the disruption of a strong ionic interaction between helices 3 and 6. J. Biol. Chem. 277:11441-49 (Pubitemid 34952912)
90. Klabunde T, Hessler G. 2002. Drug design strategies for targeting G-protein-coupled receptors. ChemBioChem 3:928-44 (Pubitemid 35189597)
91. 2-adrenergic receptor ligands. Proc. Natl. Acad. Sci. USA 106:6843-48
92. 1B-adrenergic receptor causes apoptotic neurodegeneration: multiple system atrophy. Nat. Med. 6:1388-94 (Pubitemid 32001024)
93. Julius D, Livelli TJ, Jessell TM, Axel R. 1989. Ectopic expression of the serotonin 1c receptor and the triggering of malignant transformation. Science 244:1057-62 (Pubitemid 19152293)
94. Marinissen MJ, Gutkind JS. 2001. G-protein-coupled receptors and signaling networks: emerging paradigms. Trends Pharmacol. Sci. 22:368-76 (Pubitemid 32592476)
95. Setola V, Roth BL. 2003. Why mice are neither miniature humans nor small rats: a cautionary tale involving 5-hydroxytryptamine-6 serotonin receptor species variants. Mol. Pharmacol. 64:1277-78 (Pubitemid 37532216)
96. Couzin J. 2004. Drug safety: Withdrawal of VIOXX casts a shadow over COX-2 inhibitors. Science 306:384-85 (Pubitemid 39372409)
97. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, et al. 1997. Valvular heart disease associated with fenfluramine-phentermine. N. Engl. J. Med. 337:581-88 (Pubitemid 27360757)
98. Devereux RB. 1998. Appetite suppressants and valvular heart disease. N. Engl. J. Med. 339:765-66
99. 2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102:2836-41
100. Setola V, Hufeisen SJ, Grande-Allen KJ, Vesely I, Glennon RA, et al. 2003. 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol. Pharmacol. 63:1223-29 (Pubitemid 36627216)
101. 2B receptors in the cardiopathy associated with fenfluramine. Mol. Pharmacol. 57:75-81 (Pubitemid 30033262)
102. Launay JM, Herve P, Peoc'h K, Tournois C, Callebert J, et al. 2002. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat. Med. 8:1129-35 (Pubitemid 35175968)
103. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. 2007. Dopamine agonists and the risk of cardiac-valve regurgitation. N. Engl. J. Med. 356:29-38 (Pubitemid 46041751)
104. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. 2007. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N. Engl. J. Med. 356:39-46 (Pubitemid 46041752)
105. Roth BL. 2007. Drugs and valvular heart disease. N. Engl. J. Med. 356:6-9
106. Clineschmidt BV, Hanson HM, Pflueger AB, McGuffin JC. 1977. Anorexigenic and ancillary actions of MK-212 (6-chloro-2-(1-piperazinyl)-pyrazine; CPP). Psychopharmacology 55:27-33 (Pubitemid 8223198)
107. Dourish CT. 1995. Multiple serotonin receptors: opportunities for new treatments for obesity? Obes. Res. 3(Suppl. 4):S449-62
108. 2C receptor mutant mice. Psychopharmacology 143:309-14 (Pubitemid 29204986)
109. 2 family serotonin receptors reveal novel strategies for therapeutic target development. Expert Opin. Ther. Targets 5:685-95 (Pubitemid 33781099)
110. 2C agonist, reduces body weight in obese men and women. Obesity 17:494-503
111. 2C agonist: in vitro and in vivo pharmacological characterization. J. Pharmacol. Exp. Ther. 325:577-87 (Pubitemid 351574813)
112. Valdes LJ III, Diaz JL, Paul AG. 1983. Ethnopharmacology of ska Maria Pastora (Salvia divinorum, Epling and Jativa-M.). J. Ethnopharmacol. 7:287-312 (Pubitemid 13078303)
113. Vortherms TA, Roth BL. 2006. Salvinorin A: from natural product to human therapeutics. Mol. Interv. 6: 57-65
114. Siebert DJ. 1994. Salvia divinorum and salvinorin A: new pharmacologic findings. J. Ethnopharmacol. 43:53-56 (Pubitemid 24186510)
115. Sheffler DJ, Roth BL. 2003. Salvinorin A: the "magic mint" hallucinogen finds a molecular target in the κ opioid receptor. Trends Pharmacol. Sci. 24:107-9 (Pubitemid 36293772)
116. Roth BL, Baner K, Westkaemper R, Siebert D, Rice KC, et al. 2002. Salvinorin A: a potent naturally occurring nonnitrogenous κopioid selective agonist. Proc. Natl. Acad. Sci. USA 99:11934-39 (Pubitemid 34994502)
117. Nichols DE. 2004. Hallucinogens. Pharmacol. Ther. 101:131-81
118. Chavkin C, Sud S, Jin W, Stewart J, Zjawiony JK, et al. 2004. Salvinorin A, an active component of the hallucinogenic sage Salvia divinorum is a highly efficacious κ-opioid receptor agonist: structural and functional considerations. J. Pharmacol. Exp. Ther. 308:1197-203 (Pubitemid 38263998)
119. John TF, French LG, Erlichman JS. 2006. The antinociceptive effect of salvinorin A in mice. Eur. J. Pharmacol. 545:129-33
120. McCurdy CR, Sufka KJ, Smith GH, Warnick JE, Nieto MJ. 2006. Antinociceptive profile of salvinorin A, a structurally unique K opioid receptor agonist. Pharmacol. Biochem. Behav. 83:109-13
121. Baker AK, Meert TF. 2002. Functional effects of systemically administered agonists and antagonists of |0, 6, and K opioid receptor subtypes on body temperature in mice. J. Pharmacol. Exp. Ther. 302:1253-64 (Pubitemid 34920250)
122. Yan F, Bikbulatov RV, Mocanu V, Dicheva N, Parker CE, et al. 2009. Structure-based design, synthesis, and biochemical and pharmacological characterization of novel salvinorin A analogues as active state probes of the K-opioid receptor. Biochemistry 48:6898-908
123. Hippius H. 1999. Ahistorical perspective of clozapine. J. Clin. Psychiatry 60(Suppl. 12):22-23
124. Kane J, Honigfeld G, Singer J, Meltzer H. 1988. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 45:789-96
125. Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, et al. 2003. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch. Gen. Psychiatry 60:82-91 (Pubitemid 36070868)
126. Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, et al. 2003. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharma-cology 28:519-26
127. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, et al. 2003. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28:1400-11 (Pubitemid 41070874)
128. Bohannon J. 2002. Animal models: Can a mouse be standardized? Science 298:2320-21 (Pubitemid 36014186)
129. Amsterdam JD, Brunswick DJ, HundertM. 2002. A single-site, double-blind, placebo-controlled, dose-ranging study of YKP10A-a putative, new antidepressant. Prog. Neuropsychopharmacol. Biol. Psychiatry 26:1333-38
130. Feighner JP, Ehrensing RH, Kastin AJ, Patel A, SverdlovL, etal. 2001. Double-blind, placebo-controlled study of INN 00835 (netamiftide) in the treatment of outpatients with major depression. Int. Clin. Psychopharmacol. 16:345-52 (Pubitemid 33030050)
131. Palfreyman MG, HookDJ, KlimczakLJ, BrockmanJA, Evans DM, Altar CA. 2002. Novel directions in antipsychotic target identification using gene arrays. Curr. Drug Targets CNS Neurol. Disord. 1:227-38
132. Suessbrich H, Waldegger S, Lang F, Busch AE. 1996. Blockade of HERG channels expressed inXenopus oocytes by the histamine receptor antagonists terfenadine and astemizole. FEBS Lett. 385:77-80 (Pubitemid 26153472)
133. Hopkins AL. 2009. Drug discovery: predicting promiscuity. Nature 462:167-68
134. Hopkins AL, Mason JS, Overington JP. 2006. Can we rationally design promiscuous drugs? Curr. Opin. Struct. Biol. 16:127-36 (Pubitemid 43221881)
135. Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, et al. 2009. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 460:748-52
136. Segurado R, Detera-Wadleigh SD, Levinson DF, Lewis CM, Gill M, et al. 2003. Genome scan metaanalysis of schizophrenia and bipolar disorder, part III: Bipolar disorder. Am. J. Hum. Genet. 73:49-62 (Pubitemid 36793779)
137. Oh G, Petronis A. 2008. Environmental studies of schizophrenia through the prism of epigenetics. Schizophr. Bull. 34:1122-29
138. Coyle JT, Duman RS. 2003. Finding the intracellular signaling pathways affected by mood disorder treatments. Neuron 38:157-60 (Pubitemid 36555643)
139. Gray JA, Roth BL. 2007. The pipeline and future of drug development in schizophrenia. Mol. Psychiatry 12:904-22 (Pubitemid 47482704)
140. Conn PJ, Roth BL. 2008. Opportunities and challenges of psychiatric drug discovery: roles for scientists in academic, industry, and government settings. Neuropsychopharmacology 33:2048-60 (Pubitemid 351992094)